Advice

following a full submission

febuxostat (Adenuric®) is accepted for restricted use within NHS Scotland.

Indication under review: Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence, of tophus and/or gouty
arthritis).

SMC restriction: when treatment with allopurinol is inadequate, not tolerated or contraindicated. Febuxostat is superior to allopurinol 300mg daily in reducing serum uric acid to <6mg/dL,
(360micromol/L) in patients with hyperuricaemia and gout. (NB The maximum licensed daily dose of allopurinol is 900mg.)

The economic case was demonstrated for second line use of febuxostat in patients who had an inadequate response to allopurinol, or when allopurinol is contraindicated or not tolerated.
 

Download detailed advice129KB (PDF)

Download

Medicine details

Medicine name:
febuxostat (Adenuric)
SMC ID:
637/10
Indication:
Chronic hyperuricaemia
Pharmaceutical company
Menarini Pharmaceuticals UK
BNF chapter
Musculoskeletal and joint diseases
Submission type
Full
Status
Restricted
Date advice published:
13 September 2010